 Moderna Inc MRNA shares are trading higher by 8.5 to 214.34 on continued upward momentum after the company and Merck announced mRNA-4157V940 in combination with KEYTRUDA, met the primary efficacy endpoint in the Phase 2b KEYNOTE-942 trial. 